Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of “Buy” from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has earned a consensus rating of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $23.80.

LXEO has been the subject of several research analyst reports. Leerink Partners dropped their price objective on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Wednesday, November 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday. HC Wainwright upped their target price on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Finally, Chardan Capital raised their price objective on Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock opened at $4.88 on Friday. Lexeo Therapeutics has a 1-year low of $4.78 and a 1-year high of $19.50. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $161.36 million, a PE ratio of -1.54 and a beta of 3.08. The firm’s 50 day simple moving average is $6.82 and its 200 day simple moving average is $9.41.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of LXEO. BNP Paribas Financial Markets lifted its holdings in shares of Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the last quarter. Values First Advisors Inc. purchased a new position in Lexeo Therapeutics during the third quarter valued at $67,000. SG Americas Securities LLC purchased a new position in Lexeo Therapeutics during the fourth quarter valued at $72,000. JPMorgan Chase & Co. grew its stake in shares of Lexeo Therapeutics by 135.6% in the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after acquiring an additional 5,915 shares during the last quarter. Finally, MetLife Investment Management LLC increased its holdings in shares of Lexeo Therapeutics by 121.5% during the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock valued at $129,000 after acquiring an additional 7,803 shares in the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.